Detalles de la búsqueda
1.
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
Circulation
; 134(24): 1931-1943, 2016 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27777279
2.
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Am Heart J
; 168(5): 682-9, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25440796
3.
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Atherosclerosis
; 288: 85-93, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31349086
4.
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.
J Am Heart Assoc
; 7(18): e009221, 2018 09 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30371190
5.
Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.
J Am Heart Assoc
; 6(8)2017 Aug 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28862926
6.
Unmet medical needs and therapeutic goals in the treatment of type 2 diabetes.
Curr Opin Investig Drugs
; 4(10): 1173-8, 2003 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-14649208
Resultados
1 -
6
de 6
1
Próxima >
>>